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A b s t r A c t
Background: Acquired resistance to protein C in pregnancy has been established as one of the factors associated with 
thromboembolic phenomenon, an important cause of maternal mortality and morbidity. Objectives: To establish the mean 
levels of PCA ratio (measure of protein C resistance) of among our pregnant women since maternal mortality rate of the country 
is on the increase despite efforts to reduce this trend. Materials and Methods: A prospective study was carried out in a tertiary 
institution in Enugu State, Southeastern Nigeria over the 7 months period from May 2010 to November 2010. Two hundred 
pregnant women and 50 non pregnant female controls were recruited and PCA ratio, (coagulometric assay) were determined.  
Results: There was a non significant difference between the mean and standard deviation PCA ratio of the female non pregnant 
controls and pregnant women in 2nd trimester 4.32±0.4 and 4.30±0.4 respectively. A significant difference was noted between 
the controls and pregnant women in 3rd trimester 4.32±0.4 and 3.87±0.5 respectively also between the pregnant women in their 
2nd and 3rd trimester 4.30±0.4 and 3.87±0.5 respectively. Conclusion: There is increased protein resistance C in our pregnant 
women. This may implicate thromboembolic disorders as one of the leading causes of increase maternal mortality despite a 
downward trend in the prevalence of post partum haemorrhage.
KEY WORDS: Acquired protein C resistance, maternal mortality, pregnancy, post partum hemorrhage, thromboembolic disorders






Address for correspondence 
Dr. Ukamaka Theresa Nwagha, 
Department of Haematology and Immunology, College of Medicine, 
University of Nigeria Enugu Campus, University of Nigeria Teaching Hospital 




Hemostasis heralds the healing process following tissue 
injury. It is the process of formation of a fibrin clot with 
subsequent dissolution of the clot. It is a dynamic process, 
whereby blood coagulation is initiated and terminated 
in a rapid and regulated manner.[1] The process of blood 
coagulation is initiated when sub- endothelial tissue factor 
is exposed to the blood flow, following either injury or 
activation of the endothelium.[2]
A variety of inhibitory system, which inactivates either 
serine proteases or cofactors, inhibits the coagulation 
process. A dynamic inhibitory system is generated when 
thrombin binds to its co-factor thrombomodulin, which 
is constitutively present on the vasculature, and activates 
protein C to a serine protease activated protein C.[3] 
Activated protein C inhibits the coagulation reaction by the 
proteolytic cleavages and concomitant inactivation of factor 
V, factor Va, factor VIII, and factor VIIIa.[4,5]
Normal pregnancy is associated with significant alterations 
in all aspects of the Virchow triad: Venous stasis, endothelial 
damage, and enhanced coagulation, thereby shifting the 
equilibrium towards the pro-thrombotic state.[6] These include 
increasing concentrations of most clotting factors, decreasing 
concentrations of some of the natural anticoagulants, and 
reducing fibrinolytic activity. Indeed, there is a significant 
decrease in protein S activity and progressive increase in 
resistance to activated protein C in 2nd and 3rd trimesters.[7] 
Consequently, the overall balance of hemostasis tilts towards 
apparent hyper coagulability as pregnancy progresses even 
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up to pueperium.[8] Hypercoagulability in pregnancy is 
critically, essential, for the provision of adequate hemostasis 
to the placental site and certainly acts in synergy with uterine 
contractions to prevent post-postpartum hemorrahage and 
avert maternal death.
In Nigeria and indeed most developing countries, maternal 
mortality ratio has remained unacceptably high, despite 
concerted efforts to curb the trend.[9,10] Several studies from 
different parts of Nigeria have reported conflicting figures, 
ranging from 532-2989 per 100000 live births.[9-15] These 
studies are, however, flawed as they are hospital-based 
and, therefore, does not adequately represent the entire 
population. An effort to undertake a multicenter research 
in institutions located at different socio-economic settings 
observed that the maternal mortality ratio and their causes 
varied considerably from institution to institution.[10] 
Although postpartum hemorrhage has been taunted as the 
leading cause of maternal deaths,[9,11-13] studies are beginning 
to incorporate other factors as competing contenders.[10,16-18]
With these obvious discrepancies, one wonders if it still 
appropriate to expend all energy and resources on PPH at the 
expense of other potentially fatal determinants of maternal 
deaths. It is undisputable that efforts to reduce maternal 
deaths from PPH is yielding positive result as maternal 
deaths from PPH are abating.[19-21] However, the overall 
maternal mortality rate in Nigeria is still embarrassingly 
high.[21,22] The only plausible explanation is the existence 
of a hidden, undiagnosed or under-diagnosed contributor 
to maternal deaths, which had been overshadowed by 
excessive, but deserved attention to PPH. In Nigeria and 
indeed many developing countries, many unexplained 
and unexpected, non hemorrhagic maternal deaths occur 
regularly. These deaths are sparingly reported, and even 
when reported, autopsies are rarely done. It is extremely 
likely that most of the death result from thrombo-embolic 
disease. Unfortunately, this etiological factor is usually 
placed at the bottom of the list of the common causes of 
maternal mortality in Nigeria[9-15] and hence, became a 
negligible factor in obstetric management. Indeed, thrombo 
prophylaxis is hardly ever contemplated, even with the 
existence of overt predisposing factors. This is in contrast to 
events in most developed countries where changes, which 
occur in the activity of protein C during pregnancy, has been 
documented to contribute significantly as a leading cause of 
thrombo-embolic related mortality and morbidity.[7]
As the deadline for the MDGs is fast approaching, and as the 
menace of PPH is being tackled, thrombo embolic disorders 
may begin to emerge as a leading cause of maternal deaths in 
Nigeria. Unfortunately, we are poorly equipped to perform 
proactively. It is, therefore, expedient to establish factual 
knowledge if this emerging threat must be confronted. The 
general thinking that thrombo-embolic maternal deaths are 
uncommon[10-13] in our environment must be dispelled, and 
the real danger must be exposed.
Although some Nigerian studies have examined different 
aspects of coagulation profile in pregnancy,[23-27] there 
has been none done on protein C activity in pregnancy. 
Consequently, in order to inform our people and raise 
awareness on the implication of this emergent variable in 
the etiology of maternal deaths, a major determinate of 
coagulability; the protein C activity profile is determined.
MATeRIALs AnD MeTHODs
Study area
The study was done in Enugu, the capital of Enugu state in 
Southeast Nigeria, between May and November 2010. The 
city of Enugu is situated at about 230 m above sea level. The 
population	of	the	city	is	about	464,514,	of	which,	52.1%	are	
female. Enugu state has a crude birth rate of 45 per 1000, 
crude death rate of 18 per 1000 of the population and a 
life expectancy of 51 years.[28] The maternal mortality rate 
ranges between 750 and 850 per 100,000 live births.[9,29]
Study site
University of Nigeria teaching Hospital (UNTH) antenatal 
clinics is run every working day, Monday to Friday. Patients 
are usually seen at booking every 4 weeks till 28 weeks, 
fortnightly till 36 weeks, and then, weekly till delivery. 
At booking, obstetric, medical, and surgical history is 
obtained. Gestational age is estimated from the first day of 
the last normal menstrual period and is collaborated with 
ultrasonography. The 1st trimester ultrasound, if available 
at booking, is preferred. Trimester is defined as the 1st 
trimester (<14 weeks); 2nd (14 – 27 weeks), and 3rd (>27 
weeks). Height and weight are measured, and the body mass 
index calculated. General, systemic, and obstetrics physical 
examinations are done. The following routine investigations 
are also done; hemoglobin, urinalysis, blood group, 
hemoglobin electrophoresis, fasting blood sugar, ultrasound 
assessment, and screening for syphilis, HIV, hepatitis B and C.
Sample size calculation
To calculate the minimum sample size (n) for comparing the 










where n=minimum sample size for each group
Zα=%	point	of	the	normal	distribution	corresponding	to	the	
two–sided significance level (e.g. if the significance level is 
5%,	then	Zα=1.96)
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Z=one-sided percentage point of the normal distribution; 
corresponding	 to	 the	power.	 If	 the	power	 is	80%,,	 then	Z	
-= 0.84.
σ=Population Standard deviation
δ=m2 – m1=expected difference in means
No such study has been carried out in our population; 
however, in a pilot study conducted at the commencement 
of this study using 50 gestational age matched subjects, the 
largest estimated true difference between the means was 
0.4 while the widest population standard deviation was 0.5, 
therefore, applying the formula
n =




( . . ) .
.
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[ ]
 n=25 for each group making a total of 75
In order to make provision for attrition and enhance the 
power of the study, 200 pregnant and 50 non-pregnant 
controls were recruited.
Clinical methods
This was a longitudinal study with a control arm involving 
200 normal pregnant women between the ages of 16-48 
years. Fifty (50) nonpregnant age matched controls were 
recruited from medical students and hospital staff. After 
obtaining an ethical approval from the UNTH ethical approval 
committee, and informed written consent, subjects who 
met the inclusion criteria were randomly recruited from the 
antenatal clinic by a simple random sampling technique. 
They were recruited in the 2nd trimester and were followed 
up to the 3rd trimester. Women in the 1st trimester were 
excluded because majorities of our pregnant women book 
late for antenatal care.[31-33] History, physical examination, 
and laboratory analysis were performed as earlier stated.
Inclusion criteria
•	 All	 normal	pregnant	women	 in	 the	2nd trimester who 
gave an informed consent
Exclusion criteria
•	 Women	with	 consecutive	 abortions	 before	 the	 index	
pregnancy
•	 Past	 medical	 history	 with	 underlying	 pathologies	
such as liver disease, inherited bleeding disorders, 




than 1 pint of beer/day)[32]
•	 Those	already	on	anticoagulants
•	 Complicated	 pregnancies	 (hemorrhage	 during	
pregnancy, pre-eclampsia, gestational diabetes, and 
multiple pregnancy.
Laboratory procedure
Venous samples were obtained using a 21G needle attached 
to a 5 mls syringe; 4.5 mls of blood were drawn and put into 
a	sample	bottle	containing	0.5	mls	of	3.2%	of	sodium	citrate,	
(9 parts of blood to 1 part of citrate). The blood sample was 
gently but well-mixed. For the control subjects, samples 
were collected on the 7th day of the menstrual period and 
analyzed after a negative serum beta HCG pregnancy test.
A 15-minute double centrifugation was done within one 
hour of sample collection. First, the citrated blood was 
centrifuged at 150-200 gravitational force for 15 min; a 
plastic transfer pipette was used to remove the supernatant 
platelet rich plasma, which was placed in a second plastic 
tube and re-centrifuged this time at 3000 gravitational 
under identical conditions. The resulting platelet poor 
plasma (PPP) was either tested immediately or stored in 
aliquots at in a -80oC freezer until testing.
Protein C activity was measured using a clot-based assay 
protein C activator (PCA) assay kit (Diagen UK lot no. 82, 83). 
Reagents were reconstituted, and assay procedure carried 
out according to manufacturer instructions. Clot detection 
was done using a KH202 coagulometer (Jinan Kinghawk 
Technology, China 2006-2008). This procedure measures 
the standard Activated Partial Thromboplastic Time (APTT) 
and then the protein C activator/APTT ratio (PCA/APTT). The 
ratio of PCA/APTT and the standard APTT gave the PCA ratio. 
The PCA ratio is a measure for APC resistance. Reference 
control plasmas, Diagen APC resistance plasma, (lot number 
117) were used to validate the test.
Quality control
The samples were tested in batches. Each batch was controlled 
using APC-resistant plasma. These readings are shown in 
Table 1 and Figure 1. The mean values of PCA: APTT/APTT 
was recorded in seconds. The cutoff ratio, used to determine 
increased protein C resistance for this study, was a value of 
less than or equal to 4.0 seconds. This value was determined 
in the hematology laboratory of our institution. A delta check, 
which is the difference between duplicate laboratory results, 
which exceeds a predefined limit, was applied. A value of 0.5 
was allowed between duplicates results.
Statistical analysis
Data obtained in this study was analyzed using the Statistical 
Package for Social Sciences (SPSS) version 11, Graph Pad 
Prism version 5.02, and Graph Pad Prism Stat mate version 
2.00. Graph Pad Stat mate version 2 was used to justify the 
power	of	the	study	and	to	ensure	that	it	is	above	80%,	which	
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is the minimum required power for clinical studies. Values 
were recorded in percentages and mean±standard deviation 
where applicable. For the numerical data, the one way 
analysis of variance (ANOVA) followed by Tukey’s Honestly 
Significant Difference (HSD) post hoc test was used to test 
for significant differences between the groups. The PCA ratio 
in pregnancy was compared with the values found in the 
non-pregnant female controls. Chi-square was used to test 
for significance for the non-numerical data. Values of P<0.05 
were	considered	significant	at	95%	confidence	interval.
ResULTs
Out of the 200 pregnant subjects recruited over a 7 month 
period, 145 completed the survey while a total of 55 pregnant 
subjects were lost to follow up due to change in locations, 
opting for care in other nearby hospitals and withdrawal from 
the	study.	The	resultant	compliance	rate	of	73%	(145/200)	was	
recorded. Table 2 shows the value of some socio-demographic 
characteristics. These include age, parity, weight, height, body 
mass index (BMI), and the mean gestational age.
Activated protein C APC sensitivity ratio or 
protein C activity
The Protein C Activity (PCA) was calculated using the PCA. 
APTT/ordinary APTT as shown in Table 3.
The mean APC ratio of the female non-pregnant controls 
was 4.32 ( 0.43). The pregnant subject had a mean APC ratio 
of 4.27 (0.44) in the 2nd trimester and 3.87 (0.50) in the 
3rd trimester. These changes were statistically significant, 
(P<0.0001). However, the post hoc multiple comparisons 
showed that these significant differences were primarily due 
to differences between the control subjects versus pregnant 
subjects in their 3rd trimester and also due to differences 
in the pregnant subjects between the 2nd trimester versus 
3rd trimester (P<0.001). However, the differences between 
control subjects versus the pregnant subjects in their 2nd 
trimester of pregnancy did not contribute to the significant 
change that was observed (P=0.368). The trimester related 
trend in PCA is highlighted in Figure 2.
Table 4 shows the percentage distribution of APC ratio. 
Table 1: Quality control reference figures obtained  
during the study
Test Mean values SD CV
APC resistant plasma 78.2 0.16 0.21
Table 2: Some demographic and anthropometric 
characteristics of the test and control subjects
Variables Control 2nd trimester 3rd trimester
Age (years) 23.92 (5.96) 26.68 (3.98) 26.68 (3.98)
Height (m) 1.63 (0.06) 1.57 (0.14) 1.57 (0.14)
Weight (Kg) 62.22 (8.99) 71.60 (14.52) 73.93 (11.86)
BMI (kg/m[2]) 23.19 (3.08) 29.32 (6.69) 32.67 (12.73)
Parity 0.34 (1.12) 2.50 (1.62) 2.50 (1.62)
Gestational age (Wks) – 21.2 (3.8) 32.0 (2.9)
M = Meter, Kg = Kilogram, Wks = Weeks
Table 3: Activated protein C APC sensitivity ratio or Protein C 
activity as calculated by PCA. APTT/ordinary APTT
Test Control group 2nd trimester 3rd trimester P value
APC/aPTT (secs) 158.60 (13.80)a 155.90±6.80b 150.80 (9.60)c 0.001
aPTT (secs) 39.71 (4.17)d 36.83±3.61e 39.51 (4.40)f 0.001
APC Ratio 4.32 (0.43)g 4.27±0.44h 3.87 (0.50)i 0.00l
ANOVA and post hoc multiple comparisons. *a vs. b vs. c (P<0.001); a vs. b (P=0.003);  
b vs. c (P<0.001); a vs. c (P<0.001). †d vs. e vs. f (P<0.001); d vs. e (P<0.001); e vs. f (P<0.001);  
d vs. f (P=0.692). ‡g vs. h vs. i (P<0.001); g vs. h (P=0.368); g vs. i (P<0.001); h vs. i (P<0.001).  
§P >0.05=not significant
Table 4: Percentage distribution of APC ratio in the control 
subjects and as pregnancy progressed
APC ratio Control (n/%) 2nd trimester (n/%) 3rd trimester (n/%)
≥4 42 (84) 107 (74) 56 (39)
<4 8 (16) 38 (26) 89 (61)
Total 50 (100) 145 (100) 145 (100)
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Figure 2: Trends in variation of PCA ratio among the pregnant and non 
pregnant subjects
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The female non-pregnant controls and pregnant subjects in 
their 2nd and 3rd trimester with normal APC sensitivity ratio 
of	≥	4	were	84%,	74%,	and	39%,	respectively.	Women	with	
APC	sensitivity	ratio	<	4	were	16%	for	control	26%	and	61%	
for 2nd and 3rd trimester, respectively. These differences 
were statistically significant (P<0.0001).
DIscUssIOn
All the subjects were within the reproductive age group (16 
- 48 years). Some of the subjects in the pregnant group were 
lost to follow-up. The main reason was their decision to 
get antenatal services in other hospitals nearer their areas 
of abode, after their first visit to the teaching hospital. 
Other reasons were voluntary decline from the study after 
the first sample collection, ill health, and changing of their 
geographical location.
The differences in age and parity present a selection bias 
as the study was conducted in a teaching hospital, and 
this resulted in most of the control subjects being college 
students. Expectedly, the weight and the BMI increased 
as pregnancy progressed. Though these women were 
recruited from the second semester, the amount of weight 
gained during a single pregnancy varies among women. It 
has been documented that the overall pregnancy weight 
gain for women starting pregnancy at a normal weight and 
with a BMI of 18.5 - 24.9, range from 11.4 to 15.9 kg.[34] 
In this study, the mean APC sensitivity ratio (APTT with 
APC/APTT) reduced significantly as pregnancy progressed. 
The implication is an increase in protein C resistance. This 
was similar to reports where resistance to activated protein 
C increased in the 2nd and 3rd trimesters of pregnancy.[35-37] 
Indeed, a reduction of the ratio in the 1st and 2nd trimesters 
was associated with gestational complications, such as 
pregnancy loss, pre-eclampsia, and abruptio placentae.[35]
These changes can be attributed to increase in estrogen 
levels, increased plasma volume, increased levels of some 
procoagulant e.g. Factor VIII, decreased levels of some of 
the natural anticoagulants, and diminishing fibrinolysis. [7] 
The net effect is the establishment of a physiological, 
hyper-coagulable state, which is critical in achieving minimal 
blood loss during labor. Additionally, pregnancy-induced 
physiological changes reduce blood flow in the legs and 
lead to significant venostasis.[38] The combination of these 
factors may become potentially hazardous, with great 
potential for initiating thrombo-embolic events. This 
occurs more specifically when there are other associated 
risk factors, like cesarean delivery (especially emergency 
case, black race, obesity, multiple pregnancy, heart disease, 
diabetes, sickle cell disease, smoking, anti-phospholipid 
syndrome inherited thrombophilia, and previous history of 
thrombosis.[39-41]
In Nigeria, thromboembolic disorders have been reported 
as a rare cause of maternal mortality.[9-15] This is dangerously 
misleading and can obviously not be attributed to low 
prevalence rate. The real problems involve; inadequate 
study design, under diagnosis, and missed diagnosis due 
to diagnostic constraints and challenges. Others include 
non-reporting and under-reporting of cases. Indeed, 
aversion to autopsies due to the peculiar socio-cultural and 
economic situations prevalent in our environment tends to 
aggravate the situation.
This study is one of the first in Nigeria that utilized clot- 
(coagulometric) based assay to evaluate Protein C activity. 
Clot-based assays provide a more realistic account as it also 
tests the interaction of the APC and phospholipids, the PC 
cofactor protein S and the substrate factors Va and VIIIa, 
which are all necessary for APC anticoagulant activity in 
vivo. Furthermore, it highlights the presence of activated 
protein C resistance sometimes seen in pregnancy and 
in cooperates the in vivo interaction of factors involved 
in protein C system.[42] However, the study would have 
been more robust, if the women were recruited before 
pregnancy to assess the prevalence of inherited protein C 
resistance, then followed during pregnancy and childbirth. 
This will allow caregivers to determine the role of inherited 
and/or acquired protein C resistance on pregnancy outcome. 
Further studies will address these inadequacies, including 
the evaluation of factor VIII levels, which was not assayed 
in this study. Indeed, pregnant women with complicated 
pregnancies like hypertensive disorders and gestational 
diabetes mellitus should be assessed for thrombophilic 
conditions.
It is undisputable that hypercoagulability in pregnancy is 
not uncommon in our environment, and thromboembolic 
disorders may contribute as one of the factors militating 
against the reduction of maternal mortality and morbidity. 
As the deadline for MDGs fast approaches and deaths 
from PPH regresses,[19-21] as progress toward economic, 
manpower, and technological development are being 
made, it is appropriate that strategies and policy for 
the management of thromboembolic disorders be put 
in place. This will make our practitioners to perform 
proactively and prevent the devastating consequences of 
sudden death.
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